Read by QxMD icon Read

Journal of Cancer Research and Clinical Oncology

Sophia Marie Häußler, Carmen Stromberger, Heidi Olze, Georg Seifert, Steffen Knopke, Arne Böttcher
OBJECTIVE: The purpose of this study was to assess rhabdomyosarcomas (RMS) of the head and neck in pediatric patients with regard to clinical presentation, treatment, and survival. METHODS: Data were retrospectively obtained from patient charts with regard to RMS of the head and neck diagnosed between 1996 and 2016 at a tertiary referral center. Clinical course, treatment modalities, and side effects were analyzed. Survival analysis was carried out using the Kaplan-Meier method...
November 16, 2017: Journal of Cancer Research and Clinical Oncology
Jizhen Li, Yi Liao, Jintuan Huang, Yi Sun, Hao Chen, Chunyu Chen, Senmao Li, Zuli Yang
A disintegrin and metalloprotease with motif 5(ADAMTS5) has been involved in colorectal cancer (CRC) with hypermethylation in the promoter. However, its role in CRC remains unclear. The aim of this study was to explore the clinical significance and biological effect of ADAMTS5 on colorectal carcinogenesis. Through MSP, qRT-PCR, WB and IHC analysis, followed by a variety of in vitro assays, we report the function of ADAMTS5 in CRC. ADAMTS5 was markedly hypermethylaed and downregulated in tumor tissues compared with non-tumor tissues (p < 0...
November 15, 2017: Journal of Cancer Research and Clinical Oncology
Junzhong Lin, Jianhong Peng, Yixin Zhao, Baojia Luo, Yujie Zhao, Yuxiang Deng, Qiaoqi Sui, Yuanhong Gao, Zhifan Zeng, Zhenhai Lu, Zhizhong Pan
PURPOSE: Oligometastatic disease can potentially be cured when an optimal approach is performed. Early recurrence after liver resection is an intractable problem, and the clinical implications remain unknown in colorectal liver oligometastases (CLOM) patients. This study aimed to investigate the clinical characteristics, risk factors, and prognosis related to early recurrence in these patients. METHODS: A total of 307 consecutive patients with CLOM undergoing curative liver resection were retrospectively reviewed between September 1999 and June 2016...
November 11, 2017: Journal of Cancer Research and Clinical Oncology
Ji Ma, Tengfei Li, Xinwei Han, Huifeng Yuan
OBJECTIVE: Previous studies reported that lncRNA antisense non-coding RNA in the INK4 locus (ANRIL) was upregulated in hepatocellular carcinoma (HCC) tissues and decreased expression of ANRIL could suppress cell proliferation, metastasis, and invasion and induce apoptosis of HCC cells. However, the molecular mechanism of ANRIL involved in HCC tumorigenesis is still unknown. METHODS: The expressions of ANRIL and miR-122-5p in HCC tissues and cells were quantified by qRT-PCR...
November 10, 2017: Journal of Cancer Research and Clinical Oncology
Giovanni Battista Biserni, Enrico Di Oto, Linda Eszter Moskovszky, Maria Pia Foschini, Zsuzsanna Varga
BACKGROUND: Male breast cancer is an uncommon disease often discovered in advanced stage; thus, in the setting of metastatic adenocarcinoma, breast origin must be taken to account. Breast markers as NY-BR-1, GATA-3, mammaglobin, and BRST-2 are established tools for labelling primary and metastatic female breast cancer; however, none of them has been sufficiently studied in male breast cancer. The aim of this study was to analyze the expression of these markers in male breast cancer. MATERIALS AND METHODS: Thirty consecutive cases of male breast cancer and eight loco-regional metastases were re-revaluated, assembled in tissue micro array (TMA), and stained with immunohistochemistry (IHC) for NY-BR-1, GATA-3, mammaglobin, and BRST-2...
November 7, 2017: Journal of Cancer Research and Clinical Oncology
Sibylle Schirm, Christoph Engel, Sibylle Loibl, Markus Loeffler, Markus Scholz
PURPOSE: Although G-CSF is widely used to prevent or ameliorate leukopenia during cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy parameters such as dosing and timing of cytotoxic drugs and G-CSF, G-CSF pharmaceuticals used and individual risk factors of patients. METHODS: We integrate available biological knowledge and clinical data regarding cell kinetics of bone marrow granulopoiesis, the cytotoxic effects of chemotherapy and pharmacokinetics and pharmacodynamics of G-CSF applications (filgrastim or pegfilgrastim) into a comprehensive model...
November 4, 2017: Journal of Cancer Research and Clinical Oncology
Yanlu Xiong, Lei Wang, Shan Wang, Mingxing Wang, Jinbo Zhao, Zhipei Zhang, Xiaofei Li, Lintao Jia, Yong Han
PURPOSE: In non-small cell lung cancer (NSCLC), success of targeted therapy has promoted researches explicitly orientated based on genetic background. Although PTEN deficiency is common in NSCLC, carcinogenesis about such genetic type has not been fully explored. Here, we have found that classical tumor suppressor P53 could be modulated by deacetylase sirtuin-3 (SIRT3) depending on the PTEN condition in NSCLC, which may be a novel breakpoint for handling PTEN deficiency NSCLC. METHODS: First, we examined SIRT3 and P53 expression files in PTEN-deficient NSCLC clinical samples and investigated their correlation...
November 4, 2017: Journal of Cancer Research and Clinical Oncology
Holm Eggemann, Udo Altmann, Serban-Dan Costa, Atanas Ignatov
BACKGROUND: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). PATIENTS AND METHODS: We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. RESULTS: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated...
November 2, 2017: Journal of Cancer Research and Clinical Oncology
Kenichiro Ishii, Izumi Matsuoka, Shinya Kajiwara, Takeshi Sasaki, Manabu Miki, Manabu Kato, Hideki Kanda, Kiminobu Arima, Taizo Shiraishi, Yoshiki Sugimura
PURPOSE: Docetaxel (DTX) is a standard chemotherapeutic drug for castration-resistant prostate cancer (CRPC), although adverse events are common. To overcome this problem, researchers have evaluated the efficacy of DTX treatment in combination with other drugs. Naftopidil is a tubulin-binding drug with fewer adverse events, implying the usefulness of this drug in clinical applications when combined with DTX. Here, we investigated the efficacy of additive naftopidil treatment in combination with DTX on prostate cancer (PCa) cells...
November 2, 2017: Journal of Cancer Research and Clinical Oncology
Yukiko Matsuo, Kazu Shiomi, Dai Sonoda, Masashi Mikubo, Masahito Naito, Yoshio Matsui, Tsutomu Yoshida, Yukitoshi Satoh
PURPOSE: Lung adenocarcinomas with a micropapillary pattern (MPP) are characterized by more frequent and pronounced vascular invasion, higher incidence and more advanced lymph node involvement and poorer prognosis than papillary adenocarcinomas without an MPP. Here we established a new lung cancer cell line featuring micropapillary structure. METHODS: A 73-year-old never-smoker Japanese female, presenting with an abnormal chest shadow, was diagnosed with a clinical T2aN0M0 Stage IB lung adenocarcinoma and underwent left upper lobectomy with mediastinal lymph node dissection...
November 1, 2017: Journal of Cancer Research and Clinical Oncology
Julien Taieb, Fernando Rivera, Salvatore Siena, Meinolf Karthaus, Manuel Valladares-Ayerbes, Javier Gallego, Michael Geissler, Reija Koukakis, Gaston Demonty, Marc Peeters
PURPOSE: To report exploratory analyses of early tumour shrinkage (ETS) and depth of response (DpR) in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), receiving the first-line treatment in three randomised panitumumab trials. METHODS: Data from the PRIME (NCT00364013), PEAK (NCT00819780) and PLANET (NCT00885885) studies were included. Median DpR, the proportion of patients achieving ETS ≥ 20% or ≥ 30% at week 8, and the impact of ETS and DpR (including by category) on outcome were analysed...
October 28, 2017: Journal of Cancer Research and Clinical Oncology
Juan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, Valentín García-Gutiérrez, Guillermo Ortí, Angel Ramírez-Payer, Eduardo Olavarria, Ferrán Vall-Llovera, Pilar Giraldo, Eulogio Conde, Rolando Vallansot, Jose Luis López-Lorenzo, Luis Palomera, Alberto Álvarez-Larrán, Venancio Conesa, Guiomar Bautista, Laura Casas, Frank Giles, Andreas Hochhaus, Luis Felipe Casado-Montero
Correction to: J Cancer Res Clin Oncol (2017) 143:2059-2066 DOI 10.1007/s00432-017-2445-z.
October 23, 2017: Journal of Cancer Research and Clinical Oncology
Cathleen Böhme, Marc Baron von Osthoff, Katrin Frey, Jutta Hübner
PURPOSE: Medical apps are gaining importance rapidly. Also in the field of cancer care, apps are offered. Yet, so far little is known with respect to their quality. METHODS: In a pilot phase we developed a rating tool based on formal and content-related criteria for the assessment of cancer apps. We used this instrument on cancer apps available in the App Store (iOS) concerning breast, prostate and colorectal cancer. The results were stratified according to target group, content and advertising...
October 19, 2017: Journal of Cancer Research and Clinical Oncology
Beata Biesaga, Anna Mucha-Małecka, Anna Janecka-Widła, Marta Kołodziej-Rzepa, Sława Szostek, Dorota Słonina, Aleksandra Kowalczyk, Krzysztof Halaszka, Marcin Przewoźnik
PURPOSE: To evaluate the impact of HPV16 load (VL-the number of virus genome copies per cell) and P16 expression on prognosis of patients with squamous cell carcinomas (SCCs) of head and neck (HN). MATERIALS AND METHODS: HPV16 presence was assessed in the group of 109 patients with HNSCCs by quantitative polymerase chain reaction (qPCR). VL (assessed by qPCR) and P16 expression (evaluated by immunohistochemistry) were analysed only in the subgroup of HPV16-positive tumours...
October 17, 2017: Journal of Cancer Research and Clinical Oncology
Yiliang Zhang, Yuan Ma, Yuan Li, Xuxia Shen, Yongfu Yu, Yunjian Pan, Yang Zhang, Su Yu, Difan Zheng, Yue Zhao, Hong Hu, Yihua Sun, Yawei Zhang, Jiaqing Xiang, Haiquan Chen
INTRODUCTION: Evidence shows that exon 19 deletions (19del) and exon 21 Leu858Arg point mutation (L858R) of EGFR are different in response to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in advanced lung cancers. However, the impact of the two mutational types in the early stage lung adenocarcinoma is unknown. METHODS: We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes...
October 12, 2017: Journal of Cancer Research and Clinical Oncology
Till Sebastian Clauditz, Arne Böttcher, Henning Hanken, Kerstin Borgmann, Guido Sauter, Waldemar Wilczak, Tobias Grob, Adrian Münscher
BACKGROUND: FGFR1 is a receptor tyrosine kinases involved in tumor growth signaling, survival, and differentiation in many solid cancer types. There is growing evidence that FGFR1 amplification might predict therapy response to FGFR1 inhibitors in squamous cell lung cancers. To estimate the potential applicability of anti FGFR1 therapies in squamous cell carcinomas of the head and neck, we studied patterns of FGFR1 amplification using fluorescence in situ hybridization (FISH). MATERIALS AND METHODS: A tissue microarray was constructed from 453 primary treatment-naive squamous cell carcinomas of the head and neck regions with histopathological and clinical follow-up data [including oral cavity (n = 222), oropharynx (n = 126), and larynx (n = 105)]...
October 11, 2017: Journal of Cancer Research and Clinical Oncology
Alix Augustin, Steven Le Gouill, Rémy Gressin, Aurélie Bertaut, Alain Monnereau, Anne-Sophie Woronoff, Brigitte Trétarre, Patricia Delafosse, Xavier Troussard, Anne Moreau, Olivier Hermine, Marc Maynadié
PURPOSE: Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma entity with a poor prognosis. Therapeutic advances have improved the survival of patients enrolled in clinical trials; however, their impact on patients outside clinical trials remains unclear. In this work, we compared patient outcome inside and outside clinical trials. METHODS: We identified MCL patients recorded in six French population-based registries between 2008 and 2012 to perform a comparison with patients enrolled in two prospective multicenter MCL clinical trials conducted by the LYSA group during the same period...
October 11, 2017: Journal of Cancer Research and Clinical Oncology
Jia-Yan Ni, Hong-Liang Sun, Yao-Ting Chen, Jiang-Hong Luo, Wei-Dong Wang, Xiong-Ying Jiang, Dong Chen, Lin-Feng Xu
PURPOSE: To preliminarily evaluate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable soft tissue sarcoma refractory to systemic chemotherapy. METHODS: Ten patients with refractory sarcoma who underwent DEB-TACE therapy between January 2015 and January 2017 were identified. Clinical information and radiological data were retrospectively collected to analyze tumor response, overall survival (OS), progression-free survival and adverse events (AEs)...
October 9, 2017: Journal of Cancer Research and Clinical Oncology
Jianfeng Wang, Yunze Xu, Liangsong Zhu, Yun Zou, Wen Kong, Baijun Dong, Jiwei Huang, Yonghui Chen, Wei Xue, Yiran Huang, Jin Zhang
PURPOSE: Renal cell carcinoma (RCC) is the most common malignancy of urogenital system, and patients with RCC may face a poor prognosis. However, limited curable therapeutic options are currently available. The aim of this study is to investigate the role of Cannabinoid receptor 2 (CB2) in RCC progression. METHODS: Immunohistochemistry was to investigate the expression pattern of CB2 in 418 RCC tissues and explore its prognostic function in RCC patients. Furthermore, the role of used CB2 si-RNA knockdown and inhibited by AM630, a CB2 inverse agonist, on cell proliferation, migration, and cell cycle of RCC cell lines in vitro was also investigated...
October 9, 2017: Journal of Cancer Research and Clinical Oncology
Søren Schmidt Morgen, Sidsel Fruergaard, Martin Gehrchen, Sebastian Bjørck, Svend Aage Engelholm, Benny Dahl
PURPOSE: The Tokuhashi revised score from 2005 (TR2005) is the most recommended prognostic scoring system in patients with metastatic spinal cord compression (MSCC). However, recent studies have questioned its prognostic ability and the need for a new revision has been proposed. We aimed to assess whether a revision of the TR2005 can improve the prognostic ability of the scoring system. METHODS: In 2011 and 2012, a total of 1143 consecutive patients admitted with MSCC were prospectively included in a 2011 and a 2012 cohort...
October 6, 2017: Journal of Cancer Research and Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"